Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Biovica International publ : DiviTum® acknowledged in ASCO educational book

05/22/2020 | 03:46am EST

Uppsala, Sweden, May 22, 2020. The ASCO educational book 2020 highlights DiviTum® as a solution to address unmet needs within monitoring treatment effect of CDK4/6 inhibitors.

The authors Erik S. Knudsen, PhD at Roswell Park Cancer Center, Geoffrey I. Shapiro, MD, PhD at Dana Farber Cancer Institute and Khandan Keyomarsi, PhD at MD Anderson conclude that: “These preliminary results highlight the potential for serum TK1 activity to act as a noninvasive biomarker for CDK4/6 inhibitor target engagement.” The authors also summarize the clinical trials that demonstrate the ability of DiviTum to identify CDK4/6 treatment resistance.

“It is very rewarding to receive this type of recognition from ASCO, the world's leading professional cancer organization. The authors state that DiviTum® can potentially be a tool for monitoring treatment effect of CDK4/6 inhibitors. I am thrilled that many years of clinical research by our team together with leading breast cancer clinicians has led to positive scientific review in a highly respected setting. We look forward to the results of ongoing clinical studies with DiviTum®,” said Anders Rylander, CEO of Biovica.

ASCO (American Society of Clinical Oncology) gathers cancer professionals across the world and has nearly 45,000 members. ASCO is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. Every year in conjunction with the ASCO Annual Meeting, an educational book is issued addressing important topics in oncology.

Reference:
https://ascopubs.org/doi/full/10.1200/EDBK_281085

© Modular Finance, source Nordic Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
2020BIOVICA INTERNATIONAL : carries out a directed share issue of Class B shares and..
AQ
2020BIOVICA INTERNATIONAL : intends to carry out a directed share issue of Class B s..
AQ
2020BIOVICA INTERNATIONAL : successfully completes clinical validation for DiviTum® ..
AQ
2020BIOVICA INTERNATIONAL PUBL : Notice to AGM for Biovica International AB
AQ
2020BIOVICA INTERNATIONAL AB : – Annual Report for the fiscal year 2019/2020 p..
AQ
2020BIOVICA INTERNATIONAL PUBL : completes analytical validation as part of FDA appl..
AQ
2020Biovica Year-end Report for 2019/2020
AQ
2020BIOVICA INTERNATIONAL PUBL : DiviTum® acknowledged in ASCO educational book
AQ
2020BIOVICA INTERNATIONAL PUBL : DiviTum® and TK activity acknowledged in highly ren..
AQ
2020BIOVICA INTERNATIONAL PUBL : provides market share target at today's Capital Mar..
AQ
More news
Financials
Sales 2021 3,00 M 0,36 M 0,36 M
Net income 2021 -38,5 M -4,64 M -4,64 M
Net cash 2021 134 M 16,1 M 16,1 M
P/E ratio 2021 -31,5x
Yield 2021 -
Capitalization 1 244 M 150 M 150 M
EV / Sales 2021 370x
EV / Sales 2022 26,0x
Nbr of Employees 21
Free-Float 75,2%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 67,00 SEK
Last Close Price 44,00 SEK
Spread / Highest target 134%
Spread / Average Target 52,3%
Spread / Lowest Target -29,5%
EPS Revisions
Managers and Directors
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors